Literature DB >> 24164240

Adeno-associated virus-mediated gene therapy for metabolic myopathy.

Cathryn S Mah1, Meghan S Soustek, A Gary Todd, Angela McCall, Barbara K Smith, Manuela Corti, Darin J Falk, Barry J Byrne.   

Abstract

Metabolic myopathies are a diverse group of rare diseases in which impaired breakdown of stored energy leads to profound muscle dysfunction ranging from exercise intolerance to severe muscle wasting. Metabolic myopathies are largely caused by functional deficiency of a single gene and are generally subcategorized into three major types of metabolic disease: mitochondrial, lipid, or glycogen. Treatment varies greatly depending on the biochemical nature of the disease, and unfortunately no definitive treatments exist for metabolic myopathy. Since this group of diseases is inherited, gene therapy is being explored as an approach to personalized medical treatment. Adeno-associated virus-based vectors in particular have shown to be promising in the treatment of several forms of metabolic myopathy. This review will discuss the most recent advances in gene therapy efforts for the treatment of metabolic myopathies.

Entities:  

Mesh:

Year:  2013        PMID: 24164240      PMCID: PMC3814817          DOI: 10.1089/hum.2013.2514

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  81 in total

1.  Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease.

Authors:  Mary Rucker; Thomas J Fraites; Stacy L Porvasnik; Melissa A Lewis; Irene Zolotukhin; Denise A Cloutier; Barry J Byrne
Journal:  Development       Date:  2004-06       Impact factor: 6.868

Review 2.  Advancing translational research through the NHLBI Gene Therapy Resource Program (GTRP).

Authors:  Cheryl L McDonald; Janet Benson; Kenneth Cornetta; Margaret Diggins; Julie C Johnston; Susan Sepelak; Gensheng Wang; James M Wilson; J Fraser Wright; Sonia I Skarlatos
Journal:  Hum Gene Ther Clin Dev       Date:  2013-04-03       Impact factor: 5.032

3.  Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors.

Authors:  Cathryn Mah; Christina A Pacak; Kerry O Cresawn; Lara R Deruisseau; Sean Germain; Melissa A Lewis; Denise A Cloutier; David D Fuller; Barry J Byrne
Journal:  Mol Ther       Date:  2007-01-23       Impact factor: 11.454

4.  Expression of short-chain acyl-CoA dehydrogenase (SCAD) proteins in the liver of SCAD deficient mice after hydrodynamic gene transfer.

Authors:  David A Holm; Frederik Dagnaes-Hansen; Henrik Simonsen; Niels Gregersen; Lars Bolund; Thomas G Jensen; Thomas J Corydon
Journal:  Mol Genet Metab       Date:  2003-04       Impact factor: 4.797

5.  Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors.

Authors:  Thomas J Fraites; Mary R Schleissing; R Andrew Shanely; Glenn A Walter; Denise A Cloutier; Irene Zolotukhin; Daniel F Pauly; Nina Raben; Paul H Plotz; Scott K Powers; Paul D Kessler; Barry J Byrne
Journal:  Mol Ther       Date:  2002-05       Impact factor: 11.454

6.  Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9.

Authors:  Mai K ElMallah; Darin J Falk; Michael A Lane; Thomas J Conlon; Kun-Ze Lee; Nadeem I Shafi; Paul J Reier; Barry J Byrne; David D Fuller
Journal:  Hum Gene Ther Methods       Date:  2012-04       Impact factor: 2.396

7.  Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat.

Authors:  Lawrence T Bish; Kevin Morine; Meg M Sleeper; Julio Sanmiguel; Di Wu; Guangping Gao; James M Wilson; H Lee Sweeney
Journal:  Hum Gene Ther       Date:  2008-12       Impact factor: 5.695

8.  Site-specific Mtm1 mutagenesis by an AAV-Cre vector reveals that myotubularin is essential in adult muscle.

Authors:  Romain Joubert; Alban Vignaud; Mickaël Le; Christelle Moal; Nadia Messaddeq; Anna Buj-Bello
Journal:  Hum Mol Genet       Date:  2013-02-05       Impact factor: 6.150

9.  Adenovirus-mediated delivery into myocytes of muscle glycogen phosphorylase, the enzyme deficient in patients with glycogen-storage disease type V.

Authors:  S Baqué; C B Newgard; R D Gerard; J J Guinovart; A M Gómez-Foix
Journal:  Biochem J       Date:  1994-12-15       Impact factor: 3.857

10.  AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis.

Authors:  Anna Buj-Bello; Françoise Fougerousse; Yannick Schwab; Nadia Messaddeq; Danièle Spehner; Christopher R Pierson; Muriel Durand; Christine Kretz; Olivier Danos; Anne-Marie Douar; Alan H Beggs; Patrick Schultz; Marie Montus; Patrice Denèfle; Jean-Louis Mandel
Journal:  Hum Mol Genet       Date:  2008-04-22       Impact factor: 6.150

View more
  6 in total

1.  Copackaging of multiple adeno-associated viral vectors in a single production step.

Authors:  Phillip A Doerfler; Barry J Byrne; Nathalie Clément
Journal:  Hum Gene Ther Methods       Date:  2014-09-19       Impact factor: 2.396

2.  Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease.

Authors:  Phillip A Doerfler; Adrian G Todd; Nathalie Clément; Darin J Falk; Sushrusha Nayak; Roland W Herzog; Barry J Byrne
Journal:  Hum Gene Ther       Date:  2016-01       Impact factor: 5.695

3.  Treatment of mitochondrial disorders.

Authors:  Sreenivas Avula; Sumit Parikh; Scott Demarest; Jonathan Kurz; Andrea Gropman
Journal:  Curr Treat Options Neurol       Date:  2014-06       Impact factor: 3.598

4.  Development of Gene Transfer for Induction of Antigen-specific Tolerance.

Authors:  Brandon K Sack; Roland W Herzog; Cox Terhorst; David M Markusic
Journal:  Mol Ther Methods Clin Dev       Date:  2014-04-30       Impact factor: 6.698

Review 5.  Targeted approaches to induce immune tolerance for Pompe disease therapy.

Authors:  Phillip A Doerfler; Sushrusha Nayak; Manuela Corti; Laurence Morel; Roland W Herzog; Barry J Byrne
Journal:  Mol Ther Methods Clin Dev       Date:  2016-01-27       Impact factor: 6.698

6.  A scalable method for the production of high-titer and high-quality adeno-associated type 9 vectors using the HSV platform.

Authors:  Laura Adamson-Small; Mark Potter; Darin J Falk; Brian Cleaver; Barry J Byrne; Nathalie Clément
Journal:  Mol Ther Methods Clin Dev       Date:  2016-05-11       Impact factor: 6.698

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.